Pharmaceuticals News and Research

RSS

ProteinSimple introduces Sally Western Blot

ProteinSimple today introduced Sally as the next member of the revolutionary Simple Western product family. Sally eliminates a critical bottleneck in large-scale protein research and biopharmaceutical development – manual Western Blot analysis. With Sally, researchers can perform 96 Simple Westerns in a single automated experiment.

From ProteinSimple 2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Teva launches generic Avalide and Avapro Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, the Company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide Tablets.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

Obesity drugs need more heart safety scrutiny: FDA panel

According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.

1 Apr 2012

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA).

31 Mar 2012

Best Practices develops Pharmaceutical Launch Excellence Services

The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae.

31 Mar 2012

Cortex reports net income of $832,000 for fourth quarter 2011

Cortex Pharmaceuticals, Inc. reported net income of approximately $832,000, or $0.01 per share, for the quarter ended December 31, 2011, compared with a net loss of approximately $984,000, or $0.01 per share, for the corresponding prior year quarter.

31 Mar 2012

Nile Therapeutics to sell 3.6 million shares of common stock

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.

31 Mar 2012

China Shenghuo 2011 total revenue increases 35% to $44.2 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported financial results for the year ended December 31, 2011.

31 Mar 2012

Teva introduces generic Provigil

Teva Pharmaceutical Industries Ltd. announces the launch of the authorized generic of Provigil (modafinil).

31 Mar 2012

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.

31 Mar 2012

Thermo Fisher introduces new HyPerforma S.U.B. TK system

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific HyPerforma Single-Use Bioreactor TK (S.U.B. TK), an integrated system that combines the company's proven single-use bioreactor technology with a robust controller platform that enhances functionality and greatly reduces setup times before each production run.

From Thermo Fisher Scientific Inc. 30 Mar 2012

Enrolment complete in Veloxis LCP-Tacro Phase III study in de novo kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.

29 Mar 2012

COPD Foundation to lead DRIVE4COPD campaign

The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.

29 Mar 2012